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Background and purpose — Clindamycin has not been compared 
with other antibiotics for prophylaxis in arthroplasty. Since 2009, 
the Swedish Knee Arthroplasty Register (SKAR) has been col-
lecting information on the prophylactic antibiotic regime used at 
every individual operation. In Sweden, when there is allergy to 
penicillin, clindamycin has been the recommended alternative. 
We examined whether there were differences in the rate of revi-
sion due to infection depending on which antibiotic was used as 
systemic prophylaxis.
Patients and methods — Patients who had a total knee arthro-
plasty (TKA) performed due to osteoarthritis (OA) during the 
years 2009–2015 were included in the study. Information on 
which antibiotic was used was available for 80,018 operations 
(55,530 patients). Survival statistics were used to calculate the 
rate of revision due to infection until the end of 2015, compar-
ing the group of patients who received cloxacillin with those who 
received clindamycin as systemic prophylaxis. 
Results — Cloxacillin was used in 90% of the cases, clindamy-
cin in 7%, and cephalosporins in 2%. The risk of being revised 
due to infection was higher when clindamycin was used than 
when cloxacillin was used (RR = 1.5, 95% CI: 1.2–2.0; p = 0.001). 
There was no signifi cant difference in the revision rate for other 
causes (p = 0.2). 
Interpretation — We advise that patients reporting allergic 
reaction to penicillin should have their allergic history explored. 
In the absence of a clear history of type-I allergic reaction (e.g. 
urticaria, anaphylaxis, or bronchospasm), we suggest the use of 
a third-generation cephalosporin instead of clindamycin as peri-
operative prophylaxis when undergoing a TKR. No recommenda-
tion can be given regarding patients with type-1 allergy. 
■
Prosthetic joint infection (PJI) is the most common reason 
for revision within 2 years after a primary TKA (Graves et al. 
2014, Singh et al. 2016). Prophylactic systemic antibiotics are 
an important part of the bundle of recommended preventive 
measures, with antibiotics from the beta-lactam group being 
the fi rst choice due to their effi ciency against Staphylococcus 
aureus (Parvizi et al. 2013, Kapadia et al. 2015). The effect 
of beta-lactams as prophylactic antibiotics has been proven in 
randomized controlled trials in total hip arthroplasty (Ericson 
et al. 1973, Hill et al. 1981, AlBuhairan et al. 2008, Voigt and 
Mosier 2015), and it is reasonable to anticipate their effective-
ness in knee arthroplasty as well. In Sweden, the penicillin-
ase-resistant penicillin cloxacillin has been the fi rst choice of 
perioperative antibiotic since the 1970s (Ericson et al. 1973, 
The Swedish Knee Arthroplasty Register 2016), whereas 
cephalosporins are widely used in other countries (Trampuz 
and Zimmerli 2006, de Beer et al. 2009, Stuyck et al. 2014, 
Chandrananth et al. 2016). Since the use of broad-spectrum 
antibiotics such as cephalosporins contributes to the selec-
tion of resistant bacteria, national Swedish guidelines recom-
mend limitation of their use where proper antibiotic alterna-
tives with a narrower spectrum are available (SBU 2010).  In 
geographic areas with high prevalence of methicillin-resistant 
Staphylococcus aureus (MRSA), vancomycin may be added 
to the prophylaxis (Parvizi et al. 2013,  Kapadia et al. 2015). 
Between 5% and 10% of hospitalized patients report that 
they are allergic to penicillin—women more often than men 
(Solensky 2003, Borch et al. 2006,  Macy et al. 2009). On test-
ing for type-I hypersensitivity, however, most of these patients 
prove negative (Solensky 2003, Mirakian et al. 2015). In the 
case of beta-lactam allergy, clindamycin is recommended as 
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a prophylactic antibiotic, both in national and international 
guidelines (Stefánsdóttir et al. 2014,  Kapadia et al. 2015), 
even though the effect of clindamycin as perioperative pro-
phylaxis has not—to our knowledge—been proven, either in 
randomized studies or in registry studies. 
The Swedish Knee Arthroplasty Register (SKAR), which 
was established in 1975, is the oldest national arthroplasty reg-
ister and has been shown to have a high degree of complete-
ness and validity (Robertsson et al. 2014). Having focused 
on a minimal dataset, the SKAR added several variables in 
2009, including type of antibiotic prophylaxis, height, weight, 
and the American Society of Anesthesiologists physical status 
classifi cation (ASA), to the report form that is fi lled out in the 
operation room. Thus, it has become possible to analyze pos-
sible effects of these variables on outcomes.
We investigated whether there was any difference in the rate 
of revision due to infection, depending on which antibiotic 
was used as perioperative prophylaxis. 
Patients and methods
The study population consisted of 82,752 knees in 56,650 
patients who were operated on with a primary total knee 
arthroplasty (TKA) for osteoarthritis (OA) during the years 
2009–2015. Those with ASA grade IV or V were excluded 
(0.2%), as were those who did not have complete reporting 
regarding antibiotic prophylaxis, body mass index (BMI), and 
ASA grade (3.1%). This left 80,018 primary TKA operations 
performed at 79 orthopedic departments on 55,350 patients. 
The mean age at primary operation was 69 (22–101) years and 
57% were women. The patients were divided into 4 groups 
depending on their BMI: < 25, 25–29.9, 30–39.9, and > 40. 
On the form that is fi lled out in the operation room for every 
patient, the following information regarding antibiotic pro-
phylaxis is provided: the type, the dose, the exact timing of 
the fi rst dose, how many doses are planned, and for how many 
days.
The primary outcome variable was revision due to infec-
tion, with revision being defi ned as a second surgery in which 
a component is exchanged, removed, or added (Robertsson et 
al. 2014). The diagnosis of infection was made by the treating 
doctors.  Reporting a revision to the SKAR however includes 
providing the registry with copies of medical records, and 
thereby the possibility of re-evaluating the cause of revi-
sion. In an earlier study, high accordance was found between 
reported infection and the widely used Musculoskeletal Infec-
tion Society (MSIS) criteria for PJI (Holmberg et al. 2015, 
Parvizi et al. 2011). 
In 99.9% of the operations, the perioperative antibiotic 
prophylaxis consisted of cloxacillin (90.3%), clindamycin 
(7.2%), or cephalosporins (2.4%). The cephalosporins used 
were the second-generation cephalosporin cefuroxime (90%) 
and the third-generation cefotaxime (10%). Vancomycin was 
used in only 0.04% of the operations. Cloxacillin was used at 
most hospitals, whereas 83% of the cephalosporin use was at 
4 departments (Figure 1). We decided not to compare cloxa-
cillin with cephalosporins due to the low number of depart-
ments using cephalosporins, which might lead to bias due to 
unknown confounding co-variables. The use of clindamycin 
was relatively equally spread among the hospitals (Figure 1). 
Both knees in bilaterally operated patients were included in 
the study, as this has been found not to affect the results (Rob-
ertsson and Ranstam 2003). Even so, we performed analyses 
excluding the fi rst-operated and second-operated knee in turn, 
and this did not alter the fi ndings.
Male sex is a known risk factor for revision due to PJI 
(Jämsen et al. 2009,  Namba et al. 2013). High BMI has also 
been identifi ed as a risk factor for PJI, although the BMI limits 
for increasing risk vary between studies (Namba et al. 2005, 
McElroy et al. 2013, Inacio et al. 2014). Other factors known 
to affect the complication rate are ASA grade and age (Namba 
et al. 2013, Belmont et al. 2014). The patients were followed 
until the end of 2015, giving a follow-up time with respect to 
revision of up to 7 years.
Statistics
For descriptive statistics, we used means and proportions. 
The cumulative revision rate curves were calculated using the 
life table method with 1-month intervals. Cox regression was 
used to compare the risk in patients receiving cloxacillin and 
clindamycin, adjusting for differences in age, sex, ASA class, 
and BMI. The 95% confi dence intervals (CIs) were calculated 
using the Wilson quadratic equation with Greenwood and Peto 
effective sample-size estimates (Dorey et al. 1993). The curves 
were cut off when 40 knees remained at risk. Any p-value of 
< 0.05 was considered signifi cant. The proportional-hazards 
assumption of the Cox regression model was assessed by 
visual inspection (log-minus-log plot).
Ethics, funding, and confl ict of interests
The data gathering of the Swedish Knee Arthroplasty Register 
was approved by the Ethics Board of Lund University (LU 
20-02) The study was supported by grants from the Swedish 
Association of Local Authorities and Regions (SALAR), from 
the Faculty of Medicine, Lund University, and from Stiftelsen 
för bistånd åt rörelsehindrade i Skåne. No competing interests 
declared.
Results
The completeness in the reporting of the antibiotic propylaxis 
used, ASA class, and BMI improved over the period, from 
86% in 2009 to 99% in 2015. Cloxcillin was used as peri-
operative prophylaxis in 72,223 operations, clindamycin in 
5,771, and cephalosporins in 1,938, whereas other antibiotics 
were used in only 86 cases. Use of clindamycin was more than 
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twice as common in females than in males, and cephalospo-
rins were also more commonly used in women (Table). The 
prophylaxis was administered within 15–45 minutes before 
surgery in 83% of the cloxacillin group, 81% of the clindamy-
cin group, and 79% of the cephalosporin group. The length of 
the planned prophylaxis was ≤ 24 hours in 98% of the cloxa-
cillin group, in 97% of the clindamycin group, and in 91% 
of the cephalosporin group. The planned number of cloxacil-
lin doses was most often 2 g × 3 (68%) and 2 g × 4 (27%). 
For clindamycin, they were 600 mg × 3 (79%) and 600 mg 
× 2 (13%), and for cephalosporin they were 1.5 g × 4 (48%) 
and 1.5 g × 3 (41%). In all the groups, antibiotic prophylaxis 
was started preoperatively in more than 99% of cases. Bone 
cement was used for fi xation in 95% of the operations in both 
the cloxacillin group and the clindamycin group, and in 99% 
of them in the cephalosporin group. The cement contained 
gentamicin in 99.8% of all cases. The mean length of follow-
up was 3.3 years in the cloxacillin group and 3.2 years in the 
clindamycin group.
With revision due to infection as an endpoint, there were 
723 revisions, of which 59% occurred within the fi rst 3 
months and 79% occurred within the fi rst year. Cox regression 
showed that patients who received clindamycin had a higher 
risk of revision than those who received cloxacillin, with a risk 
ratio (RR) of 1.5 (95% CI: 1.2–2.0). The cumulative hazard 
from the Cox regression is shown in Figure 2 and the unad-
justed risk of revision is shown in Figure 3. Men had a higher 
risk than women, while ASA grade-I patients had lower risk 
and ASA grade-III patients had higher risk than ASA grade-II 
patients. Age did not statistically signifi cantly affect the risk 
of revision for infection, but BMI was a signifi cant factor—
showing that patients with BMI 30–39.9 and BMI > 40 had 
higher risk than those with BMI 20–29.9. Patients with BMI < 
25 did not differ signifi cantly from those with BMI 25–29.9, 
but had lower risk than those with a BMI of 30 and over. With 
revision due to causes other than infection as an endpoint, 
there were 956 revisions—of which only 4% occurred within 
the fi rst 3 months and 25% occurred within the fi rst year. Cox 
regression showed that there was no statistically signifi cant 
difference in risk of revision in the cloxacillin and clindamycin 
groups (p = 0.2). Unlike when using revision for infection as 
endpoint, men had lower risk than women, the risk decreased 
with increasing age, and BMI class had no signifi cant effect 
Type of antibiotic used as perioperative prophylaxis, according to 
sex. Number and percentage of operations
 Women Men Total
Cloxacillin  40,238 87.7 31,994 93.7 72,232 90.3
Clindamycin  4,356 9.5 1,415 4.1 5,771 7.2
Cephalosporin  1,241 2.7 697 2.1 1,938 2.4
Other  51 0.1 35 0.1 86 0.1
Total  45,886 100 34,141 100 80,027 100
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Figure 1. For each of the hospitals, the proportion of the total number 
of arthroplasties in which a particular antibiotic was used. The hospi-
tals have been sorted according to the proportional use of cloxacillin 
(low to high).
Figure 2. Cumulative hazard of being revised for infection after adjust-
ing for age, sex, BMI, and ASA grade.
Figure 3. Unadjusted cumulative revision rate (CRR).
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on the risk. However, as when using revision for infection as 
endpoint, the ASA grade-II patients had lower risk than ASA 
grade-III patients, and although the difference in risk between 
ASA grade-I and ASA grade-II patients was not statistically 
signifi cant, the ASA grade-I patients had signifi cantly lower 
risk than ASA grade-III patients.
Discussion
To our knowledge, clindamycin has not previously been com-
pared to drugs with proven prophylactic effect against infec-
tion in arthroplasty surgery. The fi nding that patients who 
received clindamycin had a 50% higher risk of revision due to 
infection than patients who received cloxacillin is important, 
as a considerable number of patients are given clindamycin—
in our study, 7%. The randomized clinical trials that evaluated 
the effect of prophylactic systemic antibiotics were from the 
1970s and 1980s (Ericson et al. 1973, AlBuhairan et al. 2008, 
Voigt and Mosier 2015), and it is unlikely that such studies 
will be reproduced. Our study shows that registry-based stud-
ies are a valid alternative, and can provide information on the 
present performance of prophylactic antibiotics. 
There have been concerns that registries underestimate 
prosthetic joint infections (Witsø 2015). However, the main 
strength of our study is that the use of clindamycin was evenly 
distributed among the orthopedic units performing TKR, 
minimizing the risk of selection—as both groups would be 
affected by any under-reporting to the same extent. The same 
applies regarding the operational environment and regarding 
some of the factors known to affect the risk of infection, such 
as diabetes and smoking. A possible limitation of the study is 
that the registry does not have an exact defi nition of infection, 
and relies on the treating doctor’s ability to correctly diag-
nose infection. However, in an earlier study we found good 
conformity between reported infection and the MSIS criteria 
(Holmberg et al. 2015). As the main outcome variable in our 
study was revision, those infections treated with debridement 
without exchange of the tibial insert or with suppressive anti-
biotic therapy would be missed. We have no reason to believe 
that there could be differences in the choice of implant or type 
of treatment for infection related to the choice of perioperative 
antibiotic. It can also be postulated that patients with allergy 
are more prone to infection. However, we have not found any 
support for this hypothesis in the literature.
The reasons for the inferior effect of clindamycin com-
pared to cloxacillin are not clear. The fact that clindamycin is 
a bacteriostatic drug, whereas beta-lactams are bactericidal, 
may be of importance. In addition, clindamycin is distrib-
uted intracellularly to a high degree, giving dilution (from 
the larger volume of distribution) that is much higher than 
that for cloxacillin (Ghafourian et al. 2006). The dose of 
clindamycin used in Sweden was 600 mg, 2 or 3 times. It is 
possible that a higher dose of 900 mg, as has been recom-
mended (Meehan et al. 2009), might have had better effect. 
Bacterial resistance might also be a contributing factor, even 
though the proportion of Staphylococcus aureus strains in 
Sweden that are resistant to clindamycin is low (the Public 
Health Agency of Sweden).
We are not aware of any other prophylactic randomized or 
registry-based studies using clindamycin in orthopedic sur-
gery. Clindamycin has been found to be inferior to cephalo-
sporin as a prophylactic antibiotic in head and neck free tissue 
transfer (Pool et al. 2016).  
A higher proportion of women received clindamycin, prob-
ably due to the higher incidence of self-reported allergy to 
penicillin in women. This is supported by a reported incidence 
rate of penicillin allergy among women of 11%, which is con-
sistent with the level of clindamycin use in our study (Macy et 
al. 2009). It is also known that women are prescribed antibiot-
ics more often than men (Mor et al. 2015).
The prevalance of MRSA is very low in Sweden (the Public 
Health Agency of Sweden), and the main reason for using 
clindamycin as perioperative prophylaxis is therefore reported 
allergy to penicillin. Even though between 5% and 10% of 
hospitalized patients report allergy to penicillin (Borch et al. 
2006, Macy et al. 2009), almost all of these have negative 
results when tested for type-I hypersensitivity (Solensky 2003, 
Mirakian et al. 2015). Immediate type-I reactions are medi-
ated by IgE and generally occur within 1 hour of a given dose, 
and symptoms include pruritic rash, urticaria, and anaphy-
laxis (Mirakian et al. 2015). This type of reaction is very rare, 
with a reported incidence of 0.015–0.04% (Solensky 2003). 
Delayed reactions of type II–IV can cause a wide array of 
manifestations. The T-cell-mediated type-IV reactions mainly 
cause cutaneous symptoms ranging from a mild rash to severe 
muco-cutaneous reactions such as Stevens-Johnson syndrome 
(SJS) and toxic epidermal necrolysis (TEN) (Mirakian et al. 
2015, Romano et al. 2016). Cross-reactivity between penicil-
lins and cephalosporins has been reported, and earlier studies 
have indicated an incidence of 10%. However, the true inci-
dence of cross-reactivity is lower, ranging from 0% to 6% in 
more recent studies. Furthermore, the incidence is higher for 
fi rst-generation cephalosporins than for those of the second 
and third generations (Pichichero and Casey 2007, Park et al. 
2010, Ahmed et al. 2012, Terico and Gallagher 2014).
There is no evidence to support the view that vancomycin 
would perform better than clindamycin. On the contrary, a 
higher infection rate has been reported when using vancomy-
cin  than when using cefazolin or clindamycin (Ponce et al. 
2014). In England, teicoplanin is the fi rst choice in cases of 
penicillin allergy—and is even used frequently in other cases 
as well, which is probably related to the higher prevalence of 
MRSA in England than in Scandinavia (Hickson et al. 2015). 
For patients who report having penicillin allergy, or have 
penicillin allergy stated in their medical record, a thorough 
investigation of the allergic history is recommended. Patients 
with suspected type-I reactions (that is, urticaria, anaphylaxis, 
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or bronchospasm) should not be given beta-lactam antbiotic 
without previous allergic testing. Testing, consisting of a com-
bination of serology and skin tests followed by drug provoca-
tion, can safely rule out type-I allergy in many patients, and 
can be recommended where feasible (Solensky 2003, Mira-
kian et al. 2015). For patients who have experienced severe 
skin reactions such as SJS and TEN, or other life-threatening 
reactions, beta-lactams are best avoided altogether. All other 
patients with self-reported penicillin allergy can, with reason-
able safety precautions, be given second- or third-generation 
cephalosporin, which is in accordance with international 
guidelines and the proceedings of the international consensus 
meeting (Bratzler et al. 2013,  Parvizi et al. 2013). Even though 
the effect of cephalosporins has been proven in an RCT on hip 
arthroplasty (Hill et al. 1981) and not in knee arthroplasty, we 
have no reason to believe that the effect would differ between 
these types of operation.
We found no difference in the rate of revision due to causes 
other than infection depending on which antibiotic was used as 
prophylaxis. In the frequently cited  study from the Norwegian 
Arthroplasty Register, Engesaeter et al. (2003) reported fi nd-
ing a correlation between aseptic revision rate and prophylac-
tic antibiotic treatment, both systemically and in bone cement. 
Among possible explanations, they postulated that low-grade 
infections were wrongly diagnosed as aseptic loosening. The 
operations included in the Norwegian study were performed 
during the years 1987–2001 and concerned hip arthroplasty. 
Furthermore, it is possible that orthopedic surgeons today 
have a higher degree of awareness regarding infection, result-
ing in fewer undiagnosed infections.
The effect of sex, ASA grade, and BMI on infection rate was 
as expected, whereas we did not fi nd any correlation between 
age and infection rate. 
It is reasonable to believe that our fi ndings can be extended 
to hip arthroplasty, but there is a need for a separate study.
We conclude that clindamycin is inferior to cloxacillin as 
perioperative infection prophylaxis. The number of patients 
who receive clindamycin could be reduced by thorough anal-
ysis of the allergic history, and those without type-I allergy 
could safely be given a second- or third-generation cephalo-
sporin. However, for those with suspected type-I allergy, the 
possibilities of hospitals to perform testing vary. As there is no 
evidence to support the idea that it is better to replace cloxacil-
lin with antibiotic(s) other than clindamycin, we cannot give 
any clear recommendations regarding testing or treatment of 
these cases.
The study was conceived by OR, AWD, and AS. OR performed the analyses 
and wrote the initial draft. All the authors contributed to the interpretation of 
the data and to revision of the manuscript. All the authors approved the fi nal 
manuscript.
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